Product Description
Eli Lilly is developing LY-3451838 as a treatment for migraines. (Sourced from: https://trials.lilly.com/en-US/trial/283602)
Mechanisms of Action: PACAP38 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous,Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Migraine Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| J1H-MC-LAJB | P2 |
Completed |
Migraine Disorders |
2022-11-09 |